• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

细菌感染的肠外初始治疗方案：多重耐药革兰氏阴性杆菌感染——产超广谱β-内酰胺酶菌、产碳青霉烯酶肠杆菌科细菌、耐碳青霉烯鲍曼不动杆菌。

Calculated parenteral initial treatment of bacterial infections: Infections with multi-resistant Gram-negative rods - ESBL producers, carbapenemase-producing Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii.

作者信息

Grabein Béatrice, Ebenhoch Michael, Kühnen Ernst, Thalhammer Florian

机构信息

Stabsstelle Klinische Mikrobiologie und Krankenhaushygiene, Klinikum der Universität München, Munich, Germany.

Stabsstelle Hygiene, Klinische Infektiologie und Mikrobiologie, BG-Unfallklinik Murnau, Germany.

出版信息

GMS Infect Dis. 2020 Mar 26;8:Doc04. doi: 10.3205/id000048. eCollection 2020.

DOI:10.3205/id000048
PMID:32373429
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7186793/
Abstract

This is the sixteenth chapter of the guideline "Calculated initial parenteral treatment of bacterial infections in adults - update 2018" in the 2 updated version. The German guideline by the Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. (PEG) has been translated to address an international audience. Infections due to multiresistant Gram-negative rods are challenging. In this chapter recommendations for targeted therapy for infections caused by ESBL-producing Enterobacteriaceae, carbapenemase-producing Enterobacteriaceae and carbapenem-resistant are given, based on the limited available evidence.

摘要

这是《成人细菌性感染的初始肠外计算治疗指南 - 2018年更新》第二版中的第十六章。保罗·埃利希化疗协会（PEG）的德国指南已被翻译，以面向国际读者。多重耐药革兰氏阴性杆菌引起的感染具有挑战性。本章基于有限的现有证据，给出了针对产超广谱β-内酰胺酶肠杆菌科细菌、产碳青霉烯酶肠杆菌科细菌和耐碳青霉烯类细菌所致感染的靶向治疗建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/d8901ca39b29/ID-08-04-g-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/5a6fee30660a/ID-08-04-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/0da5e9bafe1a/ID-08-04-t-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/34a29c7af472/ID-08-04-t-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/4239ccff8966/ID-08-04-t-004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/05df2cbb37a5/ID-08-04-t-005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/d8901ca39b29/ID-08-04-g-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/5a6fee30660a/ID-08-04-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/0da5e9bafe1a/ID-08-04-t-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/34a29c7af472/ID-08-04-t-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/4239ccff8966/ID-08-04-t-004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/05df2cbb37a5/ID-08-04-t-005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa39/7186793/d8901ca39b29/ID-08-04-g-001.jpg

相似文献

1
Calculated parenteral initial treatment of bacterial infections: Infections with multi-resistant Gram-negative rods - ESBL producers, carbapenemase-producing Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii.细菌感染的肠外初始治疗方案：多重耐药革兰氏阴性杆菌感染——产超广谱β-内酰胺酶菌、产碳青霉烯酶肠杆菌科细菌、耐碳青霉烯鲍曼不动杆菌。
GMS Infect Dis. 2020 Mar 26;8:Doc04. doi: 10.3205/id000048. eCollection 2020.
2
Calculated parenteral initial treatment of bacterial infections: Intra-abdominal infections.细菌性感染的肠外初始治疗方案：腹腔内感染。
GMS Infect Dis. 2020 Mar 26;8:Doc13. doi: 10.3205/id000057. eCollection 2020.
3
Calculated parenteral initial treatment of bacterial infections: Infections of the kidneys and the genito-urinary tract.细菌性感染的肠外初始治疗方案：肾脏及泌尿生殖道感染。
GMS Infect Dis. 2020 Mar 26;8:Doc12. doi: 10.3205/id000056. eCollection 2020.
4
Calculated initial parenteral treatment of bacterial infections: Bacterial gastrointestinal infections.细菌性感染的初始胃肠外治疗方案：细菌性胃肠道感染
GMS Infect Dis. 2020 Mar 26;8:Doc06. doi: 10.3205/id000050. eCollection 2020.
5
Calculated parenteral initial treatment of bacterial infections: Respiratory infections.细菌性感染的肠外初始治疗方案：呼吸道感染。
GMS Infect Dis. 2020 Mar 26;8:Doc15. doi: 10.3205/id000059. eCollection 2020.
6
Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics.细菌性感染的初始肠外治疗方案计算：药代动力学与药效学
GMS Infect Dis. 2020 Mar 26;8:Doc17. doi: 10.3205/id000061. eCollection 2020.
7
Calculated parenteral initial treatment of bacterial infections: Bone and joint infections.细菌性感染的肠外初始治疗方案：骨与关节感染
GMS Infect Dis. 2020 Mar 26;8:Doc10. doi: 10.3205/id000054. eCollection 2020.
8
Calculated parenteral initial therapy of bacterial infections: Bacterial meningitis.细菌性感染的肠外初始治疗方案：细菌性脑膜炎
GMS Infect Dis. 2020 Mar 26;8:Doc07. doi: 10.3205/id000051. eCollection 2020.
9
Calculated parenteral initial treatment of bacterial infections: Infections in the ear, nose, throat and mouth and jaw area.细菌性感染的肠外初始治疗方案：耳、鼻、喉、口腔及颌面部感染。
GMS Infect Dis. 2020 Mar 26;8:Doc14. doi: 10.3205/id000058. eCollection 2020.
10
Calculated initial parenteral treatment of bacterial infections: Skin and soft tissue infections.细菌性感染的初始肠外治疗方案：皮肤及软组织感染
GMS Infect Dis. 2020 Mar 26;8:Doc11. doi: 10.3205/id000055. eCollection 2020.

引用本文的文献

1
Antimicrobial activity of cefepime-tazobactam combination against extended spectrum beta-lactamase and/or AmpC beta-lactamase- producing gram-negative bacilli.头孢吡肟-他唑巴坦合剂对产超广谱β-内酰胺酶和/或AmpCβ-内酰胺酶革兰阴性杆菌的抗菌活性。
BMC Infect Dis. 2024 Apr 23;24(1):434. doi: 10.1186/s12879-024-09296-y.
2
ESBL and carbapenemase-producing Enterobacteriaceae in infectious pleural effusions: current epidemiology at Hôpital du Mali.产超广谱β-内酰胺酶和碳青霉烯酶的肠杆菌科细菌在感染性胸腔积液中的情况：马里医院的当前流行病学
Drug Target Insights. 2023 Aug 29;17:92-100. doi: 10.33393/dti.2023.2613. eCollection 2023 Jan-Dec.
3

本文引用的文献

1
Calculated initial parenteral treatment of bacterial infections: Pharmacokinetics and pharmacodynamics.细菌性感染的初始肠外治疗方案计算：药代动力学与药效学
GMS Infect Dis. 2020 Mar 26;8:Doc17. doi: 10.3205/id000061. eCollection 2020.
2
Calculated initial parenteral treatment of bacterial infections: Sepsis.细菌性感染的初始肠外治疗方案计算：脓毒症
GMS Infect Dis. 2020 Mar 26;8:Doc09. doi: 10.3205/id000053. eCollection 2020.
3
Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae.
Spectrum of Microorganisms, Antibiotic Resistance Pattern, and Treatment Outcomes Among Patients With Empyema Thoracis: A Descriptive Cross-Sectional Study From the Bahawal Victoria Hospital Bahawalpur, Punjab, Pakistan.
脓胸患者的微生物谱、抗生素耐药模式及治疗结果：来自巴基斯坦旁遮普省巴哈瓦尔布尔巴哈瓦尔维多利亚医院的描述性横断面研究
Front Med (Lausanne). 2021 Aug 6;8:665963. doi: 10.3389/fmed.2021.665963. eCollection 2021.
4
S2k guideline "Calculated parenteral initial treatment of bacterial infections in adults - update 2018", 2 updated version: Foreword.S2k指南“成人细菌性感染的胃肠外初始治疗计算方法——2018年更新”，第2版：前言。
GMS Infect Dis. 2020 Mar 26;8:Doc20. doi: 10.3205/id000064. eCollection 2020.
5
Calculated parenteral initial treatment of bacterial infections: Intra-abdominal infections.细菌性感染的肠外初始治疗方案：腹腔内感染。
GMS Infect Dis. 2020 Mar 26;8:Doc13. doi: 10.3205/id000057. eCollection 2020.
6
Calculated initial parenteral treatment of bacterial infections: Sepsis.细菌性感染的初始肠外治疗方案计算：脓毒症
GMS Infect Dis. 2020 Mar 26;8:Doc09. doi: 10.3205/id000053. eCollection 2020.
含厄他培南的双碳青霉烯疗法治疗耐碳青霉烯肺炎克雷伯菌引起的感染
Antimicrob Agents Chemother. 2015 Nov 9;60(1):669-73. doi: 10.1128/AAC.01569-15. Print 2016 Jan.
4
Combination therapy for carbapenem-resistant Enterobacteriaceae: increasing evidence, unanswered questions, potential solutions.耐碳青霉烯类肠杆菌科细菌的联合治疗：证据不断增加、问题尚未解决、潜在解决方案
Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2307-11. doi: 10.1007/s10096-015-2486-7. Epub 2015 Sep 12.
5
In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.磷霉素对铜绿假单胞菌临床分离株的体外药效学
J Antimicrob Chemother. 2015 Nov;70(11):3042-50. doi: 10.1093/jac/dkv221. Epub 2015 Jul 24.
6
Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.一项1期研究，评估两种给药方案后血浆和上皮衬液中头孢他啶和阿维巴坦的稳态浓度。
J Antimicrob Chemother. 2015 Oct;70(10):2862-9. doi: 10.1093/jac/dkv170. Epub 2015 Jul 1.
7
Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.磷霉素的药效学：对抗菌药物耐药性临床应用的见解
Antimicrob Agents Chemother. 2015 Sep;59(9):5602-10. doi: 10.1128/AAC.00752-15. Epub 2015 Jun 29.
8
Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence.复方磺胺甲噁唑治疗不动杆菌属：当前微生物学和临床证据的综述。
Int J Antimicrob Agents. 2015 Sep;46(3):231-41. doi: 10.1016/j.ijantimicag.2015.04.002. Epub 2015 May 15.
9
Colistin: efficacy and safety in different populations.黏菌素：不同人群中的疗效与安全性
Expert Rev Clin Pharmacol. 2015;8(4):423-48. doi: 10.1586/17512433.2015.1053390. Epub 2015 Jun 3.
10
Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.头孢他啶/阿维巴坦对含KPC和SHVβ-内酰胺酶且Ω环有单个氨基酸取代的大肠杆菌同基因菌株的活性。
J Antimicrob Chemother. 2015 Aug;70(8):2279-86. doi: 10.1093/jac/dkv094. Epub 2015 May 8.